Indicated in pediatrics (6+ years old)
with moderate-to-severe atopic dermatitis

Request a Field Representative Visit

Connect with a DUPIXENT® Field Representative to get answers to any product-related questions.

DUPIXENT® clinical trials in adults (SOLO 1, SOLO 2, CHRONOS), adolescents aged 12-17 (AD-1526) and children aged 6-11 (AD-1652)

When topical prescription therapies are not advisable or not adequately controlling moderate-to-severe atopic dermatitis

DUPIXENT box and syringe.


The Freedom Support Program:

A program defined by the service we provide

PERSONALIZED support SPECIALIZED care PASSIONATE team

Sanofi Regeneron Logo

DUPIXENT® (dupilumab injection) logo


DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo